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Supplementary Figure S3 . Accessibility screen for bioorthogonal site-specific modification of azF-CCR5 variants confirmed using the N-terminal capture multiplex sandwich ISA strategy (A, inset). azF-CCR5 is captured using the N-terminal specific anti-CCR5 mAb T21/8, followed by detection using (A) anti-1D4 mAb-biotin/IRDye 680RD streptavidin to measure receptor expression, and (B) anti-FLAG pAb/IRDye 800CW anti-rabbit IgG to measure DBCO-FLAG incorporation. The data represent means with the standard error from triplicate measurements.
